Find Clinical Trial

Home » Find Clinical Trials » Impact of Daflon 500 mg on the progression of chronic venous disease and symptoms in patients operated on for varicose veins with conservation of the great saphenous vein. A multicentre, double blind randomised, placebo controlled, parallel group study. –

Impact of Daflon 500 mg on the progression of chronic venous disease and symptoms in patients operated on for varicose veins with conservation of the great saphenous vein. A multicentre, double blind randomised, placebo controlled, parallel group study. –

← Back

Study Phase	Phase 2

Therapeutic Area	Cardiovascular Diseases

Indication	venous disease

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	MICRONISED PURIFIED FLAVONOID FRACTION, S005682

Active Substance Code	S005682

Protocol Code	CL2-05682-102

EudraCT Code	2010-021270-11

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.